Starting April 21, you’ll be asked to log in or sign up for a free account after viewing 10 content pages each month.
Don’t worry—creating an account is quick and easy, and it comes with added benefits! Once logged in, you’ll not only continue accessing the content you already enjoy, but you’ll also unlock exclusive features like interactive donut plots for variant protein effects and variant impacts across the gene.
Stay tuned for these updates, and thank you for being part of our community!
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | P-MUC1C-ALLO1 CAR-T cells |
Trade Name | |
Synonyms | |
Drug Descriptions |
P-MUC1C-ALLO1 CAR-T are allogeneic T-cells engineered to target MUC1C, with potential antitumor activity (Journal for ImmunoTherapy of Cancer 2020;8, Issue Suppl 3). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | C187029 |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
P-MUC1C-ALLO1 CAR-T cells | P-MUC1C-ALLO1 CAR-T cells | 0 | 0 |
P-MUC1C-ALLO1 CAR-T cells + Rimiducid | P-MUC1C-ALLO1 CAR-T cells Rimiducid | 0 | 1 |